Anti-doxorubicin x Anti-EGFR Bispecific Antibody (IgG-IgG) (BSIG-151)

Anti-doxorubicin x Anti-EGFR Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-doxorubicin and anti-EGFR parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can be used in pretargeting system and deliver toxin to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

doxorubicin & EGFR

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Pretargeting system for toxin delivery

Related Disease

Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors

Targets

Target 1

doxorubicin

Alternative Names

doxorubicin

Target 2

EGFR

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Related products of "doxorubicin & EGFR"

See other bsAb targets related to "EGFR"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-doxorubicin x Anti-EGFR Bispecific Antibody (IgG-IgG) (BSIG-151). Click the button below to contact us or submit your feedback about this product.

Anti-doxorubicin x Anti-EGFR Bispecific Antibody (IgG-IgG) (CAT#: BSIG-151)

Specifications

Targets

Customer Reviews and Q&As